Climb Bio Inc
CLYM
查看详细走势图
4.900USD
+0.620+14.49%
收盘 12/22, 16:00（美东）报价延迟15分钟
334.10M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+14.49%
5天
+28.61%
1月
+188.24%
6月
+304.96%
今年开始到现在
+172.22%
1年
+151.28%
查看详细走势图
TradingKey Climb Bio Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值低估，机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Climb Bio Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
6
位分析师
强力买入
评级
9.200
目标均价
+408.29%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Climb Bio Inc亮点
亮点风险
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值低估
公司最新PE估值-111.94，处于3年历史低位
机构减仓
最新机构持股55.41M股，环比减少14.31%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值2.54K
活跃度增加
近期活跃度增加，过去20天平均换手率0.60
Climb Bio Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Climb Bio Inc简介
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
公司代码CLYM
公司Climb Bio Inc
CEOBrennan (Aoife M)
网址https://climbbio.com/
常见问题
Climb Bio Inc(CLYM)的当前股价是多少？
Climb Bio Inc(CLYM)的当前股价是 4.900。
Climb Bio Inc的股票代码是什么？
Climb Bio Inc的股票代码是CLYM。
Climb Bio Inc股票的52周最高点是多少？
Climb Bio Inc股票的52周最高点是4.820。
Climb Bio Inc股票的52周最低点是多少？
Climb Bio Inc股票的52周最低点是1.050。
Climb Bio Inc的市值是多少？
Climb Bio Inc的市值是334.10M。
Climb Bio Inc的净利润是多少？
Climb Bio Inc的净利润为-73.90M。
现在Climb Bio Inc(CLYM)的股票是买入、持有还是卖出？
根据分析师评级，Climb Bio Inc(CLYM)的总体评级为--，目标价格为9.200。
Climb Bio Inc(CLYM)股票的每股收益（EPS TTM）是多少
Climb Bio Inc(CLYM)股票的每股收益（EPS TTM）是-0.592。
相关品种
